Company Presentation Full year 2021











Sol Group in a glance

- Founded in 1927, is an Italian multinational company, present in 30 countries with more than 5.100 employees
- Two core, separated but integrated and synergic business areas: Technical Gas sector (production, applied research and marketing of pure, medical and industrial gases) and Home-Care service sector (supply of medical products and medical assistance services as well as equipment for home care therapy)
- Two recent businesses: Hydro Energy and Biotechnology




Sol Group in a glance

- . Solid performance in 2021:
 - 1,113 millions € of sales (+14.3%)
 - 58.5% of international revenues in 2021 (vs 23.7 % in 2000)
 - 7.2% of compound average growth rate during the last 10 years
 - 23.4% of EBITDA marging in 2021
 - 0,431 of Debt/Equity ratio; 1,19 of Debt/EBITDA ratio
 - Dividend policy: 30% average dividend pay out ratio over the last 10 years



SOL is **listed** at the Stock Exchange of Milan since July 1998





SOL has been founded in Italy (at Monza) on 1927 from the 2 **families** Annoni and Fumagalli: 90 years of history – three generations of entrepreneurs















The major Italian Chemical Companies (2021)

(million Euro)		World	Italian (million Euro)		World	Italian	
		sales	sales	(million Euro)		sales	sales
1°	Versalis	5.585	4.087	21°	Esseco Group	535	341
2°	Gruppo Mapei	3.265	1.068	22°	Fluorsid Group	444	187
3°	Radici Group	1.509	929	23°	Novamont	413	413
4°	Gruppo Bracco	1.400	740	24°	Ecofuel	398	37
5°	DiaSorin	1.238	327	25°	Gruppo Desa	343	340
6°	Gruppo SOL	1.113	468	26°	Reagens	306	132
7°	P & R Group	1.025	938	27°	FACI Group	305	124
8°	COIM Group	1.024	525	28°	Sadepan/Gruppo Saviola	289	197
9°	Gruppo SIAD	760	535	29°	Alfa Parf Group	271	68
10°	Gruppo Sapio	701	578	30°	Gruppo Metlac	263	260
11°	Gruppo Colorobbia	682	257	31°	Indena/Gr. IdB Holding	232	186
12°	Intercos Group	674	343	32°	Gruppo Silvateam	212	135
13°	Kerakoll	606	408	33°	3V Partecip. Industriali	206	146
14°	Italmatch Chemicals	603	182	34°	Sabo	202	202
15°	Gruppo Sodalis	593	369	35°	Gruppo Bozzetto	195	56
16°	Gruppo Aquafil	570	210	36°	Davines	192	192
17°	F.I.S.	562	549	37°	Gr. Durante/TLD Holding	189	187
18°	Gruppo Zobele	551	75	38°	Gruppo Coswell	174	174
19°	Gruppo Sipcam Oxon	545	301	39°	Renner Italia	172	55
20°	Gruppo Lamberti	541	262	40°	Mirato	169	169



Note: companies with majority of Italian capital; values refer to chemical sales (no pharmaceutical sales) Source: Federchimica


Sol Group - 30 years Turnover (1991-2021)









Sol Group – Consolidated sales (M€)








Sol Group







The Technical Gases Business





The Technical Gases Business

SOL Group operates in the technical gases business throughout the brand SOL

Production and distribution of Gases

A complete range of industrial gas (both atmospheric and non-atmospheric): medicinal, pure and special gases

- Oxygen
- Nitrogen
- Argon
- Hydrogen Carbon dioxide
- Acetylene
- Nitrous oxide Gas mixtures
- Ultra high purity gases
- Medical gases ◆ Gaseous
- helium
- Liquid helium
- Refrigerating gases
- ◆ Electronics gases
- Ammonia
- Combustible gases
- ◆ Sulfur oxide SO2
- Nitric oxide NO

Supply of plants, equipment, services and consultancy

Research, design, and construction of:

- Industrial gas production facilities
- Plant and equipment for gas utilization
- **Services and consultancy**

- Equipment for medical applications
- Equipment for cryogenic applications

 On-site plants
- Deep freezing tunnels
- Oxygen burners
- Ozonisers

- ◆ Medical air plants
- Welding machines and equipment





More than 100 technologies for the industrial sector






Technical Gases Business

Technical gases business (M€)	FY2021	FY2020	YoY
Sales	590	470	+ 25.4%
EBITDA	100	95	+ 5.5%
EBITDA %	17.0%	20.2%	
Investments	62	52	+ 19.0%

- In 2021 the division invested over the
 10% of its revenues.
- . 5.6% sales CAGR over the last 10 ys.








Technical Gases Business Area

ITALY performed brilliantly and the rest of the Group even more









Technical Gases Business Area

Sales and EBITDA (M€)







Technical Gases business

Market characteristics

- Resilient and growing market
- Margin protected thanks to high entry barriers
- Limited economic cycle demand dependence of each sales area
 - Broad variety and diversification of end-markets and applications
- Medium/long term contracts
- Local presence as a key factor

SOL


- · High diversification of sales area:
 - . More than 50,000 clients served;
 - More than 90 different applications for technical gases
- Long term contracts with customers:
 - Gas pipeline: up to 15 years;
 - Compressed gases: up to 5 years;
 - Cryogenic liquid gases: up to 3 years
- Strong local presence:
 - 27 countries, 38 sources and primary transformation plants, 49 secondary transformation plants.





Resilience + Growth + Demand stability + Low risk level

Primary Productions




















PLANT	SOURCE	
Falconara	Chemical plant	
Novara	Chemical plant	
Devnya	Chemical plant	
Bitola	Well	
Petrovo	Well	
BurgBrohl	Well	
Florina	Well	
Ihtiman	Bioethanol production	
Zeitz	Bioethanol production	
Biowanze	Bioethanol production	







SOL Group CO2 plants















SOL Group - H2 plant at Belinka - Slovenia





SOLGROUP

SOL Group – LHE plant (liquid helium) at Cremona - Italy









SOL Group - LHE plant (liquid helium) at Ranipet - India















SOL Group - N2O plant (nitrous oxide) at Ranipet - India












SOL Group - NOx plant (nitric oxide) and Neophyr at Monza - Italy











SOL for the Medical Sector (ex: INDIA)







SOLGROUP a breath of life

Secondary production plants (filling stations)

SOLGROUP



SOL Group – Filling Station at Budapest - Ungheria






The Home Care Business





Home Care - VIVISOL branches

leader in Europe,
operating in 14
European Countries, as
well as in Brazil, Turkey
and China through its
network of over 70
offices and service
points





Home Care - VIVISOL branches



VIVISOL Nederland – Tilburg



VIVISOL Belgium - Lessines



VIVISOL Austria – Vienna







Arnstadt



The Home Care Business

A complete range of services and technologies, specifically designed to take care of more than 500.000 patients affected by different chronic diseases

















Oxygen Therapy

Ventilation Therapy

Aerosol Therapy

Sleep Related Disorders

















Nutrition & Infusion

Advanced Home Care

Telemedicine

Palliative Care




Home Care Business

Hone Care business (M€)	FY2021	FY2020	YoY
Sales	556	537	+ 3,5%
EBITDA	161	161	
EBITDA %	28.9%	29.9%	
Investments	70	60	+ 15,6%

- VIVISOL was able to grow 3.5% in 2021, with an EBITDA margin higher than 28%.
- The Group is continuing to invest significantly in this business.








Homecare - Consolidated sales (M€)








Homecare - Consolidated Margins (M€)







Numbers of 2021





555,9 MILLIONS €

Sales FY2021

18,9
MILLIONS €
of Total Group revenues
growth in FY2021

+1,2 vs Budget



90,8 MILLIONS €

Capex FY2021

+67K

OF PATIENT
TREATMENTS GROWTH

SOLGROUP

The VIVISOL mission – the patient is changing



A virtual Hospital for real care

We care

«Allowing patients to live in their homes with parents and friends and improving quality of life.» Not just elderly patients.









Home Care Business




Key growth drivers:


- Aging population demographics
- Restructuring of Health Care Systems through de-hospitalization and home care
- Developments in portable medical technologies
- Better quality of life for Patients at home
- Increasing of respiratory and chronic pathologies



Sol Group – SALES (Home Care vs Technical Gases – tot Health Care)


Achieved 2011-2021







SOL results in Hospital sector





The Biotechnology Business






The Biotechnology Business

SOL Group is active in supplying biotechnological equipment and services to hospitals, clinics and laboratories (cryobanks, cellfactories, cryomanagement, cryotransportation)

With BIOTECHSOL and CRYOLAB is active in the area of tissue and stem cells banking and biological materials transportation.

With DIATHEVA is active in drug discovery and drug delivery (recombinant monoclonal antibodies), molecular diagnostic, GMP production of recombinant proteins

With PERSONAL GENOMICS is active in genetic analysis service and genetic testing research and development.
















The Hydro-Energy Business





The Hydro-Energy Business

- Leveraging on its core business development in the Eastern Europe, SOL entered into the Hydro-Energy sector.
- The industrial gas sector, is one of the most energy intensive one. This characteristic supported the Group decision to invest in the Hydro-Energy sector in order to enjoy synergies with its Industrial Gases Business.






Currently the company owns and operates 6 hydro-electric power plants in Slovenia (about 50 Million KWh/year), 2 plants in Albania (about 25 Million KWh/year); 4 plants in Macedonia (about 35 Million KWh/year); 4 plants in Bosnia (about 6 Million KWh/year).



2021

A Capital of Human Resources continuously growing



HR Key figures: 2021 a year to remember











Sol Group - consolidated results (2011 – 2021)


SOLGROUP



Sol Group – internazionalization



International Expansion







(Excluded sales in India)


68 JV & ACQUISITION (2001-2021)

Company		Year of acquisition	Division
TGT	Bosnia	2001	Technical Gases
ZEUS	Greece	2001	Technical Gases
BEHRINGER	Italy	2002	Technical Gases
ENERGETIKA	Slovenia	2002	Technical Gases
HOSPITAL SERVICE	Italy	2002	Home Care
TGP	Bosnia	2002	Technical Gases
ELOMED	Germany	2003	Home Care
IL POINT	Italy	2004	Home Care
OXYMED	Germany	2004	Home Care
MEDIZIN SERVICE	Germany	2006	Home Care
MEDIZIN TECHNIK	Germany	2006	Home Care
JULIA GAS	Italy	2007	Technical Gases
RESMED	Austria	2008	Home Care
BOESCH	Germany	2009	Home Care
JLV	Spain	2009	Home Care
DOLBY	UK - Scotland	2010	Home Care
FRODITHYA	Greece	2010	Home Care
MEDES	Italy	2010	Technical Gases
OSSIGEN GAS	Italy	2010	Technical Gases
SICGILSOL	India	2010	Technical Gases
GTH	Romania	2011	Technical Gases
HYDROENERGY	Albania	2011	Technical Gases
DIATHEVA	Italy	2012	Biotech
MEDICAL SYSTEM	Italy	2012	Technical Gases
VIVISOL TK	Turkey	2012	Home Care
СТВ	Germany	2014	Technical Gases
MBAR	France	2014	Home Care
SKS	Germany	2014	Technical Gases
TESI	Italy	2014	Technical Gases
VIVISOL ADRIA	Slovenia	2014	Home Care
CRYOLAB	Italia	2015	Biotech
FLOSIT	Morocco	2015	Technical Gases
INSPIRAR	Brazil	2015	Home Care
PIELMEIER	Germany	2015	Home Care

		Year of	
Company		acquisition	Division
SEVA	India	2015	Technical Gases
SONOCARE	Potugal	2015	Home Care
IRISH OXYGEN COMPANY	Ireland	2016	Technical Gases
KOMPASS	Germany	2016	Home Care
MEL	Bosnia	2016	Technical Gases
DIRECT MEDICAL	Ireland	2017	Home Care
GEBZE GAZ	Turkey	2017	Technical Gases
PERSONAL GENOMICS	Italy	2017	Biotech
RESPITEK	Turkey	2017	Home Care
REVI	Italy	2017	Technical Gases
SITEX	Switzerland	2017	Home Care
STERIMED	Italy	2017	Technical Gases
CRYOS	Italy	2018	Technical Gases
FISIOMED	Italy	2018	Home care
MEDSEVEN	Poland	2018	Home care
PALLMED	Poland	2018	Home care
MEDTEK	Germany	2018	Home care
Wanninger	Germany	2019	Home care
PPAR	Brazil	2019	Home care
Unit Care	Brazil	2019	Home care
DN GLOBAL	Brazil	2019	Home care
GLOBAR CARE	Brazil	2019	Home care
SPITEX PERSPECTA	Switzerland	2019	Home Care
SOL India	India	2021	Technical Gases
TAE Hellas	Greece	2021	Technical Gases
VIVICARE Hellas	Greece	2021	Home Care
OXYTECHNIC	Czech Republic	2021	Home Care
Shanghai Shenwei Medical Gas co. Ltd	China	2021	Technical Gases
Shanghai Mu Kang Medical Device Distribution Service co. Ltd	China	2021	Technical Gases
Shanghai Jiawei Medical Gas co. Ltd	China	2021	Technical Gases
KSD Kohlensaure-Dienst GmbH	Germany	2021	Technical Gases
ISIMED Srl	Italy	2021	Home Care
Portare LTDA	Brazil	2021	Home Care
NEMO LAB Srl	Italy	2021	Home Care

Capital Expenditures & Acquisition (2011-2021)

10 years of Capex & M&A on sales 2011-2021



High annual investments

- The Group every year invest about 16% of its revenues;
- The Sol business require a high level of investments for long term growth options;
- In 2021 almost the 61% of the Group investments in CAPEX (without M&A) was made outside Italy.





2021

A policy of strong investments also in the most difficult context





Record investments in 2021


A series of <u>structural investments</u> for the <u>growth</u> of the Group in the years to come



2021|2022 - A policy of strong investments also in the most difficult context


BOTH IN THE INDUSTRIAL & MEDICAL GAS BUSINESS AND IN HOME CARE













2021|2022 – A policy of strong investments also in the most difficult context

... and in M&A

TAE+Vivicare Greece





India: M&A strategy to boost SOL INDIA growth

SOL INDIA is mainly present in Tamil Nadu, so
we shall be focus on M&A targets that could
allow us to:

- expand our presence into the neighbouring
states (Kerala, Karnakata, and Andhris
Pradshe) or electroe our existing presence
(Guijarat);
- develop our presence into speciality gas
sector with a consolidated show-how;
- enter into a new area with a growing
merchant market (Maharrastra and NCR
region).

Sol.

lsimed in Italy



Oxytechnic in Czech Republic



Over
100 M€
in
acquisitions

DN Global & Portare in Brazil In 2022 with upper committee the committee of the post and pharmaceutical distribution company
Storage and pharmaceutical distribution company
Acquired from PPAR II late 2021, will be the new warehouse of the country of the countr

100% Pallmed/ Med7 in Poland



Shanghai Shenwei, Mu Kang and Jawei (China) Shanghal is one of 10 largest and most developed cities in the world:

More than 24 million of people with 38% over 60 years old and aging quickly
2020 ODP is US\$ 997 billion and 2020 ODP per capita is US\$ 23,000

150,000 beds in 2020 with medical insurance projected at 100% in 2022

Boardering with Jiangsu and Zhejlang provinces, that are among the most developed ones, with a ODP in excess of US\$1 trillion and an area of 25,000 square Km


10 years net profit and dividend growth

NET PROFIT





DPS - Dividend Yield




T 0,300

10Y AVERAGE PAY-OUT RATIO 30%





Shareholding information and market price



Source: Borsa Italiana

Outstanding Shares

- . 90.700.000 ordinary shares
- . par value: 0,52

Shareholding Structure

- Fumagalli and Annoni families 60%
- . Main Institutional Investors:
 - Tweedy Brown
 - Government of Norway





SOL Group - Consolidated Income Statement

(thousands Euro)			
	31.12.21	31.12.20	2021/ 2020
Net turnover	1,112,909	973,833	+ 14.3%
Total revenues	1,142,901 102.7%	996,196 102.3%	+ 14.7%
Added value	494,987 44.5%	468,401 48.1%	+ 5.7%
EBITDA	260,778 23.4%	255,392 26.2%	+ 2.1%
EBIT	135,771 12.2%	139,987 14.4%	-3.0%



SOL Group - Consolidated Income Statement

(Thousands Euro)

inousands Euro)				
	31.12.2	31.12.21		0
		%		%
Net turnover	1,112,909	100.0	973,833	100.0
Other revenues	11,060	1.0	9,875	1.0
Internal work capitalized	18,933	1.7	12,488	1.3
Total revenues	1,142,901	102.7	996,196	102.3
Raw materials	306,023	27.5	240,540	24.7
Services	319,511	28.7	277,282	28.5
Stocks	(2,380)	(0.2)	(14,459)	(1.5)
Other costs	24,761	2.2	24,432	2.5
Total costs	647,915	58.2	527,794	54.2
Added value	494,987	44.5	468,401	48.1
Labour costs	234,209	21.0	213,009	21.9
EBITDA	260,778	23.4	255,392	26.2



SOL Group - Consolidated Income Statement

	31.12.2	1	31.12.20	0
		%		%
EBITDA	260,778	23.4	255,392	26.2
Depreciation & Amortization	119,296	10.7	110,986	11.4
Other provisions	5,711	0.5	4,419	0.5
Operating income recurring	135,771	12.2	139,987	14.4
Non recurring (Income)/Charges	-	-	-	-
EBIT	135,771	12.2	139,987	14.4
Net financial	(9,843)	(0.9)	(9,810)	(1.0)
РВТ	125,928	11.3	130,177	13.4
Taxes	32,170	2.9	21,943	2.3
Net profit from ongoing operations	93,757	8.4	108,234	11.1
Minorities	(4,208)	(0.4)	(5,187)	(0.5)
NET PROFIT	89,549	8.0	103,047	10.6
EPS	0.987		1.136	



SOL Group - Consolidated Balance Sheet

(Thousands Euro)					
	31.12.21	31.12.20		31.12.21	31.12.20
Assets			Liabilities		
Net fixed assets	615.3	554.6	Shareholder's equity	698.3	635.7
Other fixed assets	237.3	196.3	Minorities	23.2	27.2
Cash and liquid assets	139.6	269.2	Financial debts	378.5	446.6
Inventory	67.3	63.3	Other non current liabilities	29.1	23.9
Net receivables	340.0	297.9	Payables	150.3	122.2
Other current assets	44.9	32.9	Other current liabilities	165.1	158.8
Total assets	1,444.4	1,414.3	Total liabilities	1,444.4	1,414.3



SOL Group - Net Financial Position

(Thousands Euro)

	31.12.21	31.12.20
Cash and cash at bank	139,642	269,181
Securities	6,834	6,300
Loans - current portion	(67,757)	(63,612)
Leases - current portion	(15,309)	(15,319)
Due to shareholders	0	(1,857)
Other financial receivables - current portion	1,882	1,166
Other financial liabilities - current portion	(1,440)	(2,589)
Short term liquidity	63,851	193,269
Investments securities	1,077	1,156
Loans - long term portion	(341,372)	(405,463)
Leases - long term portion	(34,573)	(36,488)
Due to shareholders	(100)	0
Other financial receivables - long term portion	1,544	831
Other financial liabilities - long term portion	(1,314)	(3,562)
Medium long term debt	(374,738)	(443,525)
TOTAL NET LIQUIDITY	(310,887)	(250,257)
TOTAL NET LIQUIDITY	(310,887)	(250,257



ND / E = **0.431** vs. 0.378 AT 31.12.20

CFC = 1,19 vs. 0.98 AT 31.12.20









